253 related articles for article (PubMed ID: 18687892)
1. Catalytic organometallic anticancer complexes.
Dougan SJ; Habtemariam A; McHale SE; Parsons S; Sadler PJ
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11628-33. PubMed ID: 18687892
[TBL] [Abstract][Full Text] [Related]
2. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
3. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
4. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
[TBL] [Abstract][Full Text] [Related]
5. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
6. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
7. Half-sandwich organometallic Ru and Rh complexes of (N,N) donor compounds: effect of ligand methylation on solution speciation and anticancer activity.
Mészáros JP; Pape VFS; Szakács G; Németi G; Dénes M; Holczbauer T; May NV; Enyedy ÉA
Dalton Trans; 2021 Jun; 50(23):8218-8231. PubMed ID: 34032247
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
[TBL] [Abstract][Full Text] [Related]
10. Pyrene-based fluorescent Ru(II)-arene complexes for significant biological applications: catalytic potential, DNA/protein binding, two photon cell imaging and
Pragti ; Kundu BK; Upadhyay SN; Sinha N; Ganguly R; Grabchev I; Pakhira S; Mukhopadhyay S
Dalton Trans; 2022 Mar; 51(10):3937-3953. PubMed ID: 35171173
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships for osmium(II) arene phenylazopyridine anticancer complexes functionalised with alkoxy and glycolic substituents.
Needham RJ; Bridgewater HE; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
J Inorg Biochem; 2020 Sep; 210():111154. PubMed ID: 32771772
[TBL] [Abstract][Full Text] [Related]
12. Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential.
Giannini F; Furrer J; Ibao AF; Süss-Fink G; Therrien B; Zava O; Baquie M; Dyson PJ; Stěpnička P
J Biol Inorg Chem; 2012 Aug; 17(6):951-60. PubMed ID: 22707191
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.
Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG
J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918
[TBL] [Abstract][Full Text] [Related]
14. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
15. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
17. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
[TBL] [Abstract][Full Text] [Related]
18. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
19. Catalysis of regioselective reduction of NAD+ by ruthenium(II) arene complexes under biologically relevant conditions.
Yan YK; Melchart M; Habtemariam A; Peacock AF; Sadler PJ
J Biol Inorg Chem; 2006 Jun; 11(4):483-8. PubMed ID: 16604356
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
